PAREXEL International Co. (NASDAQ: PRXL), RF Micro Device (NASDAQ: RFMD), Ecolab Inc. (NYSE: ECL), Lorillard Inc. (NYSE: LO), Altria Group (NYSE: MO) and Equity Residential (NYSE: EQR) upgraded by analysts.
PAREXEL International Co. (PRXL) was upgraded by Jefferies (NYSE:JEF) from an “Underperform” rating to a “Hold” rating. They have a price target of $19.50 on the company.
RF Micro Device (RFMD) was upgraded by Needham & Company from a “Hold” rating to a “Buy” rating. The have a price target of $7.00 on the company.
Ecolab Inc. (ECL) was upgraded by Deutsche Bank (NYSE:DB) from a “Hold” rating to a “Buy” rating. They have a price target of $55.00 on the company. They cited valuation as the catalyst behind the call.
Lorillard Inc. (LO) was upgraded by Davenport from a “Neutral” rating to a “Buy” rating. They have a price target of $120.00 on the company.
Altria Group (MO) was upgraded by Davenport from a “Neutral” rating to a “Buy” rating. They have a price target of $31.00 on the company.
Equity Residential (EQR) was upgraded by FBR Capital from an “Underperform” rating to a “Market Perform” rating.
Showing posts with label PAREXEL International. Show all posts
Showing posts with label PAREXEL International. Show all posts
Thursday, August 11, 2011
Tuesday, February 1, 2011
Baidu.com (Nasdaq:BIDU), Parexel (Nasdaq:PRXL), Orexigen (Nasdaq:OREX), AMD (NYSE:AMD) Among Big Movers Today
While most people today know about Orexigen (Nasdaq:OREX), which has dropped over 70 percent on the news their diet pill had been rejected by the FDA, other big movers today include Baidu.com (Nasdaq:BIDU), Parexel International (Nasdaq:PRXL) and Advanced Micro Devices Inc. (NYSE:AMD).
Also plunging were shares of Parexel International Corp., which fell after the pharmaceutical research contractor lowered its guidance for fiscal 2011, citing slow progress in signing new contracts with drugmakers.
Shares of Advanced Micro Devices Inc. continued to rise on Intel's (NASDAQ:INTC) chip problems and fallout from the unexpected firing of their CEO which brought the shares down.
Baidu.com continues to soar as they tripled their profit in the last quarter, beating analysts' estimates and looking good going forward.
Parexel International Corp. was trading at $20.99, dropping $2.22, or 9.56 percent, as of 3:32 PM EST. Orexion was at $2.60, plummeting $6.49, or 71.40 percent. AMD was up to $8.22, gaining $0.39, or 4.98 percent. Baidu.com was trading at $119.17, gaining $10.54, or 9.70 percent.
Also plunging were shares of Parexel International Corp., which fell after the pharmaceutical research contractor lowered its guidance for fiscal 2011, citing slow progress in signing new contracts with drugmakers.
Shares of Advanced Micro Devices Inc. continued to rise on Intel's (NASDAQ:INTC) chip problems and fallout from the unexpected firing of their CEO which brought the shares down.
Baidu.com continues to soar as they tripled their profit in the last quarter, beating analysts' estimates and looking good going forward.
Parexel International Corp. was trading at $20.99, dropping $2.22, or 9.56 percent, as of 3:32 PM EST. Orexion was at $2.60, plummeting $6.49, or 71.40 percent. AMD was up to $8.22, gaining $0.39, or 4.98 percent. Baidu.com was trading at $119.17, gaining $10.54, or 9.70 percent.
Monday, December 6, 2010
PAREXEL International (NASDAQ:PRXL) Ready to Provide Improved Returns
PAREXEL International (NASDAQ:PRXL) has generated a lot more consternation among shareholders than profits, and it seems a growing number are getting even more frustrated over the situation.
Barclays (NYSE:BCS) commented saying, "We recognize some investors might be frustrated that PRXL always appears to be in investment mode. We believe recent share gains by PRXL are the result of long-term investments to build a global infrastructure, offering some vindication for management who bore criticism because these investments suppressed margins below industry norms. Today, margins are being impacted by LEAP, a major operational improvement initiative, and its e-clinical business. Still, PRXL expects to deliver -100 bps of margin improvement while these strategic initiatives are implemented. We think management recognizes the need to strike a balance between solidifying/enhancing PRXL's competitive positioning while also providing evidence of improving returns."
Barclays reiterates their "Overweight" rating on PAREXEL International, which closed Monday at $18.60, gaining $0.33, or 1.81 percent. They have a price target of $25 on them.
Barclays (NYSE:BCS) commented saying, "We recognize some investors might be frustrated that PRXL always appears to be in investment mode. We believe recent share gains by PRXL are the result of long-term investments to build a global infrastructure, offering some vindication for management who bore criticism because these investments suppressed margins below industry norms. Today, margins are being impacted by LEAP, a major operational improvement initiative, and its e-clinical business. Still, PRXL expects to deliver -100 bps of margin improvement while these strategic initiatives are implemented. We think management recognizes the need to strike a balance between solidifying/enhancing PRXL's competitive positioning while also providing evidence of improving returns."
Barclays reiterates their "Overweight" rating on PAREXEL International, which closed Monday at $18.60, gaining $0.33, or 1.81 percent. They have a price target of $25 on them.
Subscribe to:
Posts (Atom)